Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Guillem Argilés


Guillem Argilés

Institute: Vall d’Hebron University Hospital
Vall d'Hebron Institute of Oncology (VHIO)


Dr Guillem Argilés, has been a member of the Gastrointestinal Malignancies Division at the Vall d’Hebrón University Hospital since 2014. He began the early steps of his career focused on translational research by obtaining his Medical Oncology specialisation in 2011 under the supervision of Prof José Baselga, at the Vall d’Hebron University Hospital. In 2011 Dr Argilés joined the Phase 1 and Developmental Therapeutics Division of this institution for a fellowship stage in molecular therapeutics. During this period, he had the opportunity to be involved in the pre-clinical and early clinical studies that set the basis for further clinical development of some of the main molecularly-driven drugs currently emerging to clinical practice such as PI3K-MAPK, Wnt, Sonic Hedgehog, TGF-beta or Notch pathway inhibitors. Due to his interest in the field of metastatic colorectal cancer in 2014 Dr Argilés joined the Gastrointestinal Malignancies Division, at the Vall d’Hebrón University Hospital as staff member under the supervision of Prof Josep Tabernero.

Guillem Argilés' career path seeks to expand the therapeutic universe of metastatic colorectal cancer by improving the acknowledgement of the biological processes behind these tumours. In this regard, he is currently involved in several translational lines of investigation like the development of new preclinical models that allow fast and reliable bedside-to-bench-and-back-to-the-bedside strategies for tailoring therapeutic strategies in colorectal cancer. Dr Argiles' further fields of investigation are new immunotherapy approaches for non-hypermutant CRC patients and the identification of guiding biomarkers for new therapeutic interventions in CRC.

Last update: October 2017

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.